https://www.bioworld.com/rss en-us The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors. http://www.bioworld.com/articles/732350 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732350-ollins-330m-series-b-underscores-rise-of-china-origin-newco-model Close-up of a human eye featuring a dollar sign in the iris A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic. http://www.bioworld.com/articles/732274 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732274-oblenios-62m-series-b-for-trispecific-antibody-in-autoimmune-diseases Antibodies illustration A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic. http://www.bioworld.com/articles/732161 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732161-oblenios-62m-series-b-for-trispecific-antibody-in-autoimmune-diseases Antibodies illustration The oversubscribed $330 million series B round secured by Ollin Biosciences Inc. marks more than another large venture round in ophthalmology. It also highlights an emerging biotech financing model in which Chinese pharma companies discover and clinically validate promising drugs before handing global development to well-capitalized U.S. startups backed by blue-chip venture investors. http://www.bioworld.com/articles/732160 Thu, 25 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732160-ollins-330m-series-b-underscores-rise-of-china-origin-newco-model Close-up of a human eye featuring a dollar sign in the iris Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half-lives that are designed to offer improvements over existing classes of monoclonal antibodies for treating chronic inflammatory diseases. http://www.bioworld.com/articles/732046 Mon, 22 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732046-bionyra-closes-165m-series-a-to-develop-antibodies-for-inflammation Art concept for monoclonal antibodies Advanced penile cancer (PeCa) is a rare cancer affecting the genitourinary tract with a 5-year survival rate of about 10% when metastatic. First-line therapies achieve objective response rates of 40%-50%, while immunotherapy has not been established. http://www.bioworld.com/articles/732013 Thu, 18 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732013-cc-3-antibody-shows-antitumoral-activity-in-penile-cancer Acumen Pharmaceuticals Inc. has nominated ACU-301 and ACU-401 as development candidates in its Enhanced Brain Delivery (EBD) program as treatments for Alzheimer’s disease. http://www.bioworld.com/articles/731990 Wed, 17 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731990-acumen-selects-development-candidates-for-alzheimers-disease Amyloid beta peptides on neurons Alzheimer's disease: Amyloid beta peptides accumulate to form amyloid plaques on neurons. China’s National Medical Products Administration has approved Suzhou Alphamab Co. Ltd.’s HER2 bispecific antibody, anbenitamab (KN-026), through priority review for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received at least one trastuzumab-containing regimen. http://www.bioworld.com/articles/731979 Tue, 16 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731979-china-clears-alphamabs-her2-bispecific-antibody-in-gastric-cancer Stomach cross-section on scientific background China’s National Medical Products Administration has approved Suzhou Alphamab Co. Ltd.’s HER2 bispecific antibody, anbenitamab (KN-026), through priority review for adults with locally advanced or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma who have received at least one trastuzumab-containing regimen. http://www.bioworld.com/articles/731801 Thu, 11 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731801-china-clears-alphamabs-her2-bispecific-antibody-in-gastric-cancer Stomach cross-section on scientific background If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base. http://www.bioworld.com/articles/731829 Tue, 09 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731829-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins China compass If the 2026 American Society of Clinical Oncology (ASCO) annual meeting in Chicago from May 30 to June 3 demonstrated anything about the evolution of China’s biotechnology sector, it was that the industry’s center of gravity is shifting. While Chinese companies once relied heavily on PD-1 antibodies and licensing deals to gain international visibility, this year’s oral presentations showcased a broader innovation base. http://www.bioworld.com/articles/731634 Fri, 05 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731634-asco-2026-chinese-biopharma-arrives-at-asco-with-pivotal-wins China compass Cytomx Therapeutics Inc. and Regeneron Pharmaceuticals Inc., which inked a bispecifics-focused collaboration worth up to $2 billion in 2022, agreed to broaden their efforts in an expanded deal that provides Cytomx with additional funding up front as it advances its promising colorectal cancer candidate, varsetatug masetecan (Varseta-M), and fills the gap left by the recently terminated agreement with Astellas Pharma Inc. http://www.bioworld.com/articles/731540 Wed, 03 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731540-cytomx-regeneron-expand-bispecifics-deal-to-potential-4b Digital handshake Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top cancer immunotherapy for patients with non-small-cell lung cancer with bispecific antibodies targeting PD-(L)1 and VEGF. http://www.bioworld.com/articles/731513 Mon, 01 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731513-asco-2026-pd-l1-x-vegf-bispecifics-fight-it-out Bispecific antibodies with heavy chain in green and pink, light chain in blue and yellow Biotle has received a clinical trial notice from China’s National Medical Products Administration (NMPA) for its IND application for BTL-203, the company’s bispecific FcRn inhibitor being developed for the treatment of multiple autoimmune diseases. http://www.bioworld.com/articles/731272 Tue, 26 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731272-biotles-fcrn-inhibitor-btl-203-cleared-for-clinic-in-china Green and red bispecific antibodies Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders. http://www.bioworld.com/articles/731224 Tue, 12 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731224-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific Eye, currency symbols and globe Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders. http://www.bioworld.com/articles/731193 Tue, 12 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/731193-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific Eye, currency symbols and globe Curacle Co. Ltd. inked a potential $1.07 billion deal with U.S.-based “newco” Memento Medicines on May 10, granting the latter exclusive global rights to develop and commercialize preclinical TIE2/VEGF-directed bispecific antibody MT-103 for retinal disorders. http://www.bioworld.com/articles/731030 Mon, 11 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/731030-curacle-memento-ink-1b-deal-for-ocular-tie2-vegf-bispecific Eye, currency symbols and globe Harbour Biomed has gained IND clearance from the FDA for HBM-7004, enabling the initiation of a first-in-human phase I trial in subjects with advanced solid tumors. http://www.bioworld.com/articles/730950 Fri, 08 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730950-fda-clears-ind-for-harbour-biomeds-hbm-7004 Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc., of Hong Kong, and undergoing phase III testing in first-line squamous non-small-cell lung cancer (NSCLC). http://www.bioworld.com/articles/730921 Tue, 05 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730921-how-to-summit-up-dis-harmoni-on-ivonescimab-nsclc-phase-iii Xray showing lung cancer on tablet Next-generation T-cell engager (TCE) specialist Cytospire Therapeutics Ltd. has raised £61 million (US$82.7 million) in a series A round, equipping it to advance the lead program CYT-X300 to the clinic in the treatment of EGFR-positive solid tumors. The company’s pan gamma delta (γδ) TCEs are designed to overcome problems with cytokine release syndrome, on-target effects on healthy cells, and the excessive activation of CD3 that have occurred with earlier bispecific antibodies that bind to the CD3 receptor on T cells. http://www.bioworld.com/articles/730879 Tue, 05 May 2026 09:00:00 -0400 https://www.bioworld.com/articles/730879-cytospire-raises-61m-series-a-to-target-egfr-in-solid-tumors The epidermal growth factor receptor in the inactive (left) and active (right) form. The epidermal growth factor receptor in the inactive (left) and active (right) form. Wall Street pundits were divided about the likely fate of ivonescimab, Summit Therapeutics Inc.’s bispecific antibody partnered with Akeso Pharmaceuticals Inc., of Hong Kong, and undergoing phase III testing in first-line squamous non-small-cell lung cancer (NSCLC). http://www.bioworld.com/articles/730767 Fri, 01 May 2026 12:00:00 -0400 https://www.bioworld.com/articles/730767-how-to-summit-up-dis-harmoni-on-ivonescimab-nsclc-phase-iii Xray showing lung cancer on tablet Akeso Pharmaceuticals Inc. has raised the bar for next-generation immuno-oncology, reporting more than 23 months median overall survival in pancreatic cancer with its PD-1/CTLA-4 bispecific antibody cadonilimab, as emerging competitors begin to post earlier signals across solid tumors at the American Association for Cancer Research annual meeting in San Diego April 17 to 22. http://www.bioworld.com/articles/730786 Tue, 28 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730786-akeso-sets-durability-bar-as-immuno-oncology-20-race-heats-up Pancreas anatomy illustration Having already hit the primary endpoint of overall response rate in the phase II/III Companion-002 study testing the bispecific antibody tovecimig in biliary tract cancer, Compass Therapeutics Inc. rolled out new data from the same experiment and plans to meet with the U.S. FDA to discuss a BLA. Shares of the Boston-based firm (NASDAQ:CMPX) closed April 27 at $1.79, down about 64%, or $3.23, as Wall Street sifted the results. http://www.bioworld.com/articles/730640 Mon, 27 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730640-s-os-compass-phase-ii-iii-biliary-data-mixed-ahoy-fda Illustration of cancer in the bile ducts Ferrosa Therapeutics AG has announced a $3.5 million seed financing to support the development of a first-in-class bispecific antibody (FRS-101) to treat anemia of inflammation across chronic kidney disease, autoimmune disease and oncology indications. http://www.bioworld.com/articles/730634 Fri, 24 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730634-seed-funding-at-ferrosa-therapeutics Coins and seedling Incyte Corp. has developed and presented data for their CD70xCD3 bispecific antibody INCA-036873, which was designed to activate T cells and kill tumoral cells expressing CD70. http://www.bioworld.com/articles/730586 Thu, 23 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730586-inca-036873-appears-to-be-potent-in-cd70-expressing-cancer 3d rendering of bispecific antibodies Akeso Pharmaceuticals Inc. has raised the bar for next-generation immuno-oncology, reporting more than 23 months median overall survival in pancreatic cancer with its PD-1/CTLA-4 bispecific antibody cadonilimab, as emerging competitors begin to post earlier signals across solid tumors at the American Association for Cancer Research annual meeting in San Diego April 17 to 22. http://www.bioworld.com/articles/730500 Wed, 22 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730500-akeso-sets-durability-bar-as-immuno-oncology-20-race-heats-up Pancreas anatomy illustration Researchers from Elpiscience Biopharmaceuticals Inc. hypothesized that dual targeting of the TL1A/DR3 and IL-23 signaling pathways with a single bispecific antibody would exert superior efficacy by reshaping the immune landscape in disorders such as inflammatory bowel disease (IBD). The company has developed a bispecific antibody targeting both TL1A/DR3 and IL-23p19 – ES-302 – for the treatment of IBD. http://www.bioworld.com/articles/730557 Wed, 22 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730557-elpisciences-bispecific-antibody-es-302-reduces-disease-activity-in-ibd-model Illustration of intestinal track Shanghai Junshi Biosciences Co. Ltd reported early clinical signals across its next-generation immuno-oncology pipeline, including response rates of up to 71% in metastatic colorectal cancer and 45.5% in hepatocellular carcinoma, at the American Association for Cancer Research meeting in San Diego. http://www.bioworld.com/articles/730486 Tue, 21 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730486-early-data-position-junshi-in-next-gen-immuno-oncology-race Illustration of cancer cells and immunotherapy treatment Mabwell (Shanghai) Bioscience Co. Ltd.’s has announced IND acceptance by China’s National Medical Products Administration (NMPA) for the company’s LILRB4/CD3 T-cell engager bispecific antibody 6MW5311. The drug candidate is being developed for hematologic malignancies, specifically acute myeloid leukemia (AML), chronic myelomonocytic leukemia and multiple myeloma. http://www.bioworld.com/articles/730428 Thu, 16 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730428-chinas-nmpa-accepts-mabwells-ind-application-for-6mw5311 Microscopic image of acute myeloid leukemia (AML) cells. Acute myeloid leukemia cells. Credit: Cincinnati Children's Founded amid the booming next-generation antibody-drug conjugate (ADC) space, Sidewinder Therapeutics Inc. has emerged from stealth with an oversubscribed $137 million series B round and plans to advance a lead program into the clinic in 2027. http://www.bioworld.com/articles/730275 Thu, 09 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730275-sidewinders-bispecific-adc-approach-draws-137m-series-b Blue digital dollar sign